Drug Profile
INM 004
Alternative Names: Anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment; INM-004Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Inmunova
- Developer Exeltis; Inmunova
- Class Fab fragments; Immunoglobulin fragments; Immunoglobulins; Immunoproteins; Polyclonal antibodies; Serum globulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Haemolytic uraemic syndrome
Most Recent Events
- 21 Mar 2024 INM 004 receives Orphan Drug status for Haemolytic anaemia in USA, prior to March 2024 (Inmunova pipeline, March 2024)
- 21 Mar 2024 INM 004 receives Orphan Drug status for Haemolytic uraemic syndrome in European Union, prior to March 2024 (Inmunova pipeline, March 2024)
- 21 Mar 2024 INM 004 receives Rare Pediatric Disease Designation for Haemolytic uraemic syndrome in USA, prior to March 2024 (Inmunova pipeline, March 2024)